The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Quality-Adjusted Life Years

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Quality-Adjusted Life Years


Psychiatry related information on Quality-Adjusted Life Years


High impact information on Quality-Adjusted Life Years


Chemical compound and disease context of Quality-Adjusted Life Years


Biological context of Quality-Adjusted Life Years


Associations of Quality-Adjusted Life Years with chemical compounds

  • RESULTS: Both strategies were similarly effective (4.33 quality-adjusted life years per patient), with omeprazole less expensive than LNF ($6053 vs. $9482 per patient) [17].
  • RESULTS OF SENSITIVITY ANALYSIS: When late complications were assumed to occur 25% less frequently in patients who received unfractionated heparin, the incremental cost-effectiveness ratio increased to almost $75,000 per QALY gained [18].
  • Patients receiving amiodarone live for 3.68 quality-adjusted life-years and have a lifetime expenditure of $51,000 [19].
  • RESULTS OF SENSITIVITY ANALYSIS: From the societal perspective, the cost per QALY gained associated with sildenafil was less than $50,000 if treatment-related morbidity was less than 0.8% per year, mortality was less than 0.55% per year, treatment was successful in more than 40.2% of patients, or sildenafil cost less than $244 per month [20].
  • 0. RESULTS: Compared with a watchful waiting approach, the incremental cost-effectiveness ratio for a strategy of screen and treat with alendronate at a BMD T score of <-1.0 was $92,600 per quality-adjusted life year (QALY) gained [21].

Gene context of Quality-Adjusted Life Years

  • The cost-utility ratios for infliximab treatment range from 16,000 Euros to almost 166,000/QALY (quality adjusted life-year) gained, the studies investigating etanercept treatment show a ratio of approximately 25,000 Euros and 120,000/QALY gained [22].
  • OBJECTIVE: To analyse the cost utility of adalimumab, on both incremental cost and incremental quality adjusted life years (QALYs), versus traditional disease modifying antirheumatic drugs and the other tumour necrosis factor (TNF) antagonists suitable for submission to the Swedish LFN (Pharmaceutical Benefit Board) [23].
  • The incremental cost per QALY of tPA remained under $60,000 if the survival benefit was half that seen in the GUSTO trial [24].
  • Costs/QALY gained discounted at 3% were $205,186 using the QWB and $32,643 using the CHRD [25].
  • Previous pharmacoeconomic studies of IFN beta have suggested that benefits can only be achieved at extremely high cost, with reported cost-effectiveness measures of up to 1 million pounds sterling (Pound) per quality-adjusted life year (QALY) [1995 values] [26].

Analytical, diagnostic and therapeutic context of Quality-Adjusted Life Years


  1. The cost-effectiveness of preventing AIDS-related opportunistic infections. Freedberg, K.A., Scharfstein, J.A., Seage, G.R., Losina, E., Weinstein, M.C., Craven, D.E., Paltiel, A.D. JAMA (1998) [Pubmed]
  2. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Pinkerton, S.D., Holtgrave, D.R., Pinkerton, H.J. Arch. Intern. Med. (1997) [Pubmed]
  3. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Gazelle, G.S., Hunink, M.G., Kuntz, K.M., McMahon, P.M., Halpern, E.F., Beinfeld, M., Lester, J.S., Tanabe, K.K., Weinstein, M.C. Ann. Surg. (2003) [Pubmed]
  4. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? Mar, J., Rodríguez-Artalejo, F. J. Hypertens. (2001) [Pubmed]
  5. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. Reed, S.D., Radeva, J.I., Glendenning, G.A., Saad, F., Schulman, K.A. J. Urol. (2004) [Pubmed]
  6. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. Bolin, K., Lindgren, B., Willers, S. Chest (2006) [Pubmed]
  7. Valuing the effects of sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value. Freemantle, N. BMJ (2000) [Pubmed]
  8. A cost-effectiveness clinical decision analysis model for schizophrenia. Palmer, C.S., Revicki, D.A., Genduso, L.A., Hamilton, S.H., Brown, R.E. The American journal of managed care. (1998) [Pubmed]
  9. The cost-effectiveness of air bags by seating position. Graham, J.D., Thompson, K.M., Goldie, S.J., Segui-Gomez, M., Weinstein, M.C. JAMA (1997) [Pubmed]
  10. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. Fiscella, K., Franks, P. JAMA (1996) [Pubmed]
  11. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. Gage, B.F., Cardinalli, A.B., Albers, G.W., Owens, D.K. JAMA (1995) [Pubmed]
  12. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Arseneau, K.O., Cohn, S.M., Cominelli, F., Connors, A.F. Gastroenterology (2001) [Pubmed]
  13. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Warren, E., Ward, S., Gordois, A., Scuffham, P. Clinical therapeutics. (2004) [Pubmed]
  14. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Kuehne, F.C., Bethe, U., Freedberg, K., Goldie, S.J. Arch. Intern. Med. (2002) [Pubmed]
  15. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. Lyseng-Williamson, K.A., Plosker, G.L. PharmacoEconomics. (2004) [Pubmed]
  16. Cost-effectiveness of prenatal screening for postpartum thyroiditis. Bonds, D.E., Freedberg, K.A. Journal of women's health & gender-based medicine. (2001) [Pubmed]
  17. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Heudebert, G.R., Marks, R., Wilcox, C.M., Centor, R.M. Gastroenterology (1997) [Pubmed]
  18. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Gould, M.K., Dembitzer, A.D., Sanders, G.D., Garber, A.M. Ann. Intern. Med. (1999) [Pubmed]
  19. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Owens, D.K., Sanders, G.D., Harris, R.A., McDonald, K.M., Heidenreich, P.A., Dembitzer, A.D., Hlatky, M.A. Ann. Intern. Med. (1997) [Pubmed]
  20. The cost-effectiveness of sildenafil. Smith, K.J., Roberts, M.S. Ann. Intern. Med. (2000) [Pubmed]
  21. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Solomon, D.H., Kuntz, K.M. Arthritis Rheum. (2000) [Pubmed]
  22. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis. Merkesdal, S., Ruof, J., Mittendorf, T., Zeidler, H. Expert opinion on pharmacotherapy. (2004) [Pubmed]
  23. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Bansback, N.J., Brennan, A., Ghatnekar, O. Ann. Rheum. Dis. (2005) [Pubmed]
  24. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Kalish, S.C., Gurwitz, J.H., Krumholz, H.M., Avorn, J. Journal of general internal medicine : official journal of the Society for Research and Education in Primary Care Internal Medicine. (1995) [Pubmed]
  25. Economic evaluation of aquatic exercise for persons with osteoarthritis. Patrick, D.L., Ramsey, S.D., Spencer, A.C., Kinne, S., Belza, B., Topolski, T.D. Medical care. (2001) [Pubmed]
  26. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Kendrick, M., Johnson, K.I. PharmacoEconomics. (2000) [Pubmed]
  27. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Catherwood, E., Fitzpatrick, W.D., Greenberg, M.L., Holzberger, P.T., Malenka, D.J., Gerling, B.R., Birkmeyer, J.D. Ann. Intern. Med. (1999) [Pubmed]
  28. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Goldie, S.J., Kaplan, J.E., Losina, E., Weinstein, M.C., Paltiel, A.D., Seage, G.R., Craven, D.E., Kimmel, A.D., Zhang, H., Cohen, C.J., Freedberg, K.A. Arch. Intern. Med. (2002) [Pubmed]
  29. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. Klarenbach, S.W., Pannu, N., Tonelli, M.A., Manns, B.J. Crit. Care Med. (2006) [Pubmed]
  30. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. AuBuchon, J.P., Birkmeyer, J.D., Busch, M.P. Transfusion (1997) [Pubmed]
  31. Is Adjuvant Therapy for Older Patients with Node (+) Early Breast Cancercost-effective?*. Naeim, A., Keeler, E.B. Breast Cancer Res. Treat. (2005) [Pubmed]
WikiGenes - Universities